The Russian Covid-19 vaccine was highly effective in testing, the study reveals, driving Moscow’s ambitions to launch
Novavax stock rises more than 20% after the study of the COVID-19 vaccine shows almost 90% effectiveness in the UK, but less against the new South African variant
Johnson & Johnson targets 100 million doses of vaccine by spring. The stock market is counting on that.
